צמיחת רווחי EPS רבעונית zentaris.com (AEZS)
Aeterna Zentaris (AEZS) is expanding its network of partner clinics through licensing deals in the mature diagnostics market. The quarterly EPS growth rate on this chart clearly demonstrates the financial dynamics, where the current metric equals 0.00. Revenues are based on Macrilen test sales and royalties. Stable demand for specialized studies makes this defensive business resilient to economic fluctuations.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%9E%D7%A9%D7%A0%D7%94%20%D7%9C%D7%A9%D7%A0%D7%94%20%D7%91-12%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_AEZS_-_Aeterna-Zentaris_-_Year-over-year-earnings-per-share-growth-for-the-last-12-months "AEZS: צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים Aeterna Zentaris Inc. 04.07.2022 - 17.08.2024 | 👁️GURU.Markets👁️")
zentaris.com (AEZS) - פילוחי מדדים ודוחות פיננסיים
Investors assess capital risks through net income dynamics, where any deviation from the trend signals potential volatility. For Aeterna Zentaris (AEZS), which focuses on the commercialization of tests and endocrinology developments, the quarterly EPS growth rate measures the speed of change in earnings per share, allowing for the identification of business value growth phases and the probability of generating alpha during an upward trend.
